| 摘要 |
Disclosed is a new treatment for men with prostatic cancer involving combination therapy of a 5 alpha -reductase inhibitor, i.e., a 17 beta -substituted 4-azasteroid, a 17 beta -substituted non-azasteroid, 17 beta -acyl-3-carboxyandrost-3,5-diene, benzoylaminophenoxybutanoic acid derivative, fused benz(thio)amide or cinnamoylamide derivative, aromatic 1,2-diethers or thioethers, aromatic ortho acylaminophenoxy alkanoic acids, ortho thioalkylacylamino-phenoxy alkanoic acids, pharmaceutically acceptable salts and esters thereof, and particularly finasteride, in combination with an antiandrogen, i.e. flutamide. Pharmaceutical compositions useful for treatment are also disclosed.
|
